Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
RXRX
RXRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
RXRX News
AI Drives Transformation in Genomics and Biological Manufacturing
5d ago
Newsfilter
11 Stocks That Have Plummeted and Appear to Be Good Investment Opportunities
5d ago
Barron's
Salesforce Shares and 10 Other Stocks That Have Plummeted and Appear to Be Good Investments
5d ago
Barron's
Recursion Pharmaceuticals Leverages AI for Accelerated Drug Development
Feb 07 2026
Fool
OpenAI Considers Investment in Biotech Sector
Feb 03 2026
seekingalpha
VentriPoint Diagnostics Accelerates Commercialization of Cardiac Imaging Technology
Jan 29 2026
PRnewswire
VentriPoint Diagnostics Accelerates Commercialization of Cardiac Imaging Technology
Jan 29 2026
Newsfilter
High-Growth Stocks Underperform in 2025, Recovery Expected in 2026
Jan 29 2026
Fool
Recursion Pharmaceuticals Faces Challenges and Opportunities
Jan 29 2026
Fool
Recursion Pharmaceuticals Faces Uncertain Future Amid Stock Decline
Jan 29 2026
NASDAQ.COM
Meta and Apple See Significant AI Investment Growth, Recursion Faces Challenges
Jan 16 2026
NASDAQ.COM
Meta and Apple See Significant AI Investment Growth, Recursion High Risk
Jan 16 2026
Fool
Divergence in Short Interest Among Mid to Mega-Cap Stocks Highlights Investor Sentiment
Jan 16 2026
seekingalpha
Recursion Pharmaceuticals Faces Challenge as Eli Lilly Plans Largest AI Supercomputer
Jan 01 2026
Fool
Recursion Pharmaceuticals Chases Clinical Wins as Eli Lilly Builds Largest AI Supercomputer
Jan 01 2026
NASDAQ.COM
Recursion Pharmaceuticals (RXRX) Upgraded to Overweight by JPMorgan with $11 Price Target
Dec 31 2025
Yahoo Finance
Show More News
